INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $303,787 | +18.5% | 22,620 | +9.2% | 0.02% | +11.8% |
| Q4 2022 | $256,344 | -7.5% | 20,723 | +4.5% | 0.02% | -5.6% |
| Q3 2022 | $277,000 | -9.8% | 19,838 | -10.9% | 0.02% | +12.5% |
| Q2 2022 | $307,000 | +8.9% | 22,260 | +28.2% | 0.02% | +6.7% |
| Q1 2022 | $282,000 | +24.8% | 17,360 | +25.1% | 0.02% | +7.1% |
| Q4 2021 | $226,000 | -27.8% | 13,874 | -11.4% | 0.01% | -17.6% |
| Q2 2021 | $313,000 | +7.9% | 15,664 | +24.7% | 0.02% | 0.0% |
| Q1 2021 | $290,000 | – | 12,563 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |